Ratio of Oxygen Saturation to Inspired Oxygen, ROX Index, Modified ROX Index to Predict High Flow Cannula Success in COVID-19 Patients: Multicenter Validation Study
16
Issued Date
2023-01-01
Resource Type
ISSN
1936900X
eISSN
19369018
Scopus ID
2-s2.0-85162268272
Pubmed ID
37278775
Journal Title
Western Journal of Emergency Medicine
Volume
24
Issue
3
Start Page
511
End Page
521
Rights Holder(s)
SCOPUS
Bibliographic Citation
Western Journal of Emergency Medicine Vol.24 No.3 (2023) , 511-521
Suggested Citation
Ruangsomboon O., Jirathanavichai S., Phanprasert N., Puchongmart C., Boonmee P., Thirawattanasoot N., Dorongthom T., Monsomboon A., Praphruetkit N. Ratio of Oxygen Saturation to Inspired Oxygen, ROX Index, Modified ROX Index to Predict High Flow Cannula Success in COVID-19 Patients: Multicenter Validation Study. Western Journal of Emergency Medicine Vol.24 No.3 (2023) , 511-521. 521. doi:10.5811/westjem.58311 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/87740
Title
Ratio of Oxygen Saturation to Inspired Oxygen, ROX Index, Modified ROX Index to Predict High Flow Cannula Success in COVID-19 Patients: Multicenter Validation Study
Other Contributor(s)
Abstract
Introduction: High-flow nasal cannula (HFNC) is a respiratory support measure for coronavirus 2019 (COVID-19) patients that has been increasingly used in the emergency department (ED). Although the respiratory rate oxygenation (ROX) index can predict HFNC success, its utility in emergency COVID-19 patients has not been well-established. Also, no studies have compared it to its simpler component, the oxygen saturation to fraction of inspired oxygen (SpO2/FiO2 [SF]) ratio, or its modified version incorporating heart rate. Therefore, we aimed to compare the utility of the SF ratio, the ROX index (SF ratio/respiratory rate), and the modified ROX index (ROX index/heart rate) in predicting HFNC success in emergency COVID-19 patients. Methods: We conducted this multicenter retrospective study at five EDs in Thailand between January–December 2021. Adult patients with COVID-19 treated with HFNC in the ED were included. The three study parameters were recorded at 0 and 2 hours. The primary outcome was HFNC success, defined as no requirement of mechanical ventilation at HFNC termination. Results: A total of 173 patients were recruited; 55 (31.8%) had successful treatment. The two-hour SF ratio yielded the highest discrimination capacity (AUROC 0.651, 95% CI 0.558-0.744), followed by two-hour ROX and modified ROX indices (AUROC 0.612 and 0.606, respectively). The two-hour SF ratio also had the best calibration and overall model performance. At its optimal cut-point of 128.19, it gave a balanced sensitivity (65.3%) and specificity (61.8%). The two-hour SF≥128.19 was also significantly and independently associated with HFNC failure (adjusted odds ratio 0.29, 95% CI 0.13-0.65; P=0.003). Conclusion: The SF ratio predicted HFNC success better than the ROX and modified ROX indices in ED patients with COVID-19. With its simplicity and efficiency, it may be the appropriate tool to guide management and ED disposition for COVID-19 patients receiving HFNC in the ED.